Browse: Home / Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine

Menu

Skip to content
  • Home
  • About Us
  • Contact Us
  • Submit News
Header image

Cambodian TribuneLogo

Latest Cambodian News

Menu

Skip to content
  • General
  • Economy
  • Information
  • Fashion
  • Self Care
  • Athletic
  • Domestic Affairs
  • Legal
  • PRESS RELEASES
  • Beijing House Church Pastor Denied Pension Amid Ongoing Crackdown on Worship
  • COVID-19: Another Patient Recovered
  • Economic Diplomacy Strategy 2021-2023 Launched
  • Hong Kong Healthcare Volunteer Jailed For Four Years Over 2019 Protest
  • Cambodian PM Receives Courtesy Call from New Indian Ambassador

Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine

Posted by admin on September 16, 2014 in Health Care | 16 Views

SAN DIEGO, Sept. 17, 2014 /PRNewswire/ — Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company (NYSE: LLY). Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.

Logo – http://photos.prnewswire.com/prnh/20140820/138306

Lilly developed enzastaurin in a variety of indications, including in Phase 2 and Phase 3 clinical trials for diffuse large B-cell lymphoma (DLBCL). In studies conducted by Lilly, enzastaurin achieved promising clinical results in the DLBCL induction setting in Phase 2 trials, but did not meet the primary endpoint in the DLBCL maintenance setting in the Phase 3 study.  A meaningful subset of patients showed significantly improved progression-free survival and Denovo Biopharma intends to conduct genetic analysis to identify biomarkers that are related to this outcome. By identifying genomic biomarkers that correlate with patients’ responsiveness to treatment, Denovo plans to screen for appropriate patient subsets for enrollment in future clinical trials that the company plans to conduct.

"We appreciate Lilly’s extensive efforts in the development of enzastaurin to date.  As our first late-stage asset acquired from a premier pharmaceutical company, this high quality data package will enable Denovo to conduct our retrospective biomarker discovery," said Michael F. Haller, Ph.D., Denovo Biopharma’s Chief Operating Officer.  "Our biomarker discovery efforts take only a few months, so when combined with Lilly’s existing data package, we should be able to rapidly initiate a biomarker validation clinical trial for the original indication (DLBCL). We are actively seeking to acquire additional drugs in late-stage development where we can utilize our biomarker discovery platform to personalize and advance other potential treatments in similar fashion."

About Enzastaurin

Enzastaurin (DB102, formerly LY317615 HCl) is an investigational oral small molecule, serine/threonine kinase inhibitor of the PKC beta and AKT pathways [1] [2] and has been studied in more than 3,000 patients across a range of solid and hematological tumor types. Diffuse large B-cell lymphoma occurs in approximately 25,000 patients annually in the U.S. Enzastaurin has received orphan drug designation from the FDA and EMA.

About Denovo Biopharma

Denovo Biopharma is a privately-held biotechnology company that provides novel and proprietary biomarker approaches to personalized drug development, including re-evaluating medicines that have failed in general patient populations by personalizing them for the original indication. The company offers the first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology may be especially useful for compounds with suboptimal late-stage trial results.  By identifying biomarkers correlated with patients’ responses to drug candidates retrospectively, Denovo enables the design and execution of follow-on clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. For additional information please visit www.denovobiopharma.com.

Contact:
Michael Haller, Chief Operating Officer
Denovo Biopharma, LLC
(858) 876-4012
mhaller@denovobiopharma.com

[1] Graff JR, et al. Cancer Res. 2005; 65:7462-7469
[2] Brautigam K, et al. Transl Oncol. 2009; 2; 164-173.

Posted in Health Care | Tagged BIO, HEA, MTC, PDT, PHA, TRI

Related Posts

Missing imageDKSH Supports Growth for Vitabiotics in Hong Kong and Malaysia→

Missing imageSphenopalatine Ganglion Stimulation in the Pathway CH-1 Study Reduces Headache Burden Before and After Sustained Periods of Cluster Attack Remission→

Missing imageLatin American Contract Research Organizations Set to Get More Local Outsourcing Opportunities→

Missing imageJapan Helps Strengthen Community Healthcare in Kampong Cham Province→

Search

Pages

  • Home
  • About Us
  • Contact Us
  • Submit News

Categories

Calendar

January 2021
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Dec    

Advertisement

Latest News

  • Missing image

    Beijing House Church Pastor Denied Pension Amid Ongoing Crackdown on Worship

    January 18, 2021 / User2
  • Missing image

    COVID-19: Another Patient Recovered

    January 18, 2021 / User2
  • Missing image

    Economic Diplomacy Strategy 2021-2023 Launched

    January 18, 2021 / User2
  • Missing image

    Hong Kong Healthcare Volunteer Jailed For Four Years Over 2019 Protest

    January 18, 2021 / User2
  • Missing image

    Cambodian PM Receives Courtesy Call from New Indian Ambassador

    January 18, 2021 / User2
  • Missing image

    Sarus Crane Still Exist but Number Seeming Drop

    January 18, 2021 / User2
  • Missing image

    Japan Provides US$227,736 for Improving Firefighting Capability of Phnom Penh Administration

    January 18, 2021 / User2
  • Missing image

    COVID-19: Three Recovered; Three Infected

    January 17, 2021 / User2
  • Missing image

    PM Hun Sen to Be the First Volunteer for Chinese Vaccine

    January 17, 2021 / User2
  • Missing image

    Cambodia’s Mekong River Believed to be a Healthiest Habitat of Endangered Giant Freshwater Stingray

    January 17, 2021 / User2
  • Missing image

    COVID-19: 10 New Infections Reported

    January 16, 2021 / User2
  • Facebook
  • Pinterest
  • Tumblr
  • Twitter

Pages

  • About Us
  • Contact Us
  • Submit News

Categories

 

Recent Posts

  • Beijing House Church Pastor Denied Pension Amid Ongoing Crackdown on Worship January 18, 2021
  • COVID-19: Another Patient Recovered January 18, 2021
  • Economic Diplomacy Strategy 2021-2023 Launched January 18, 2021
 

Search

Archives

 

About Us

Cambodia Tribune is a website which acts as an information bank in which news and press releases from various sources are updated on a regular basis. The information is associated with Cambodia and features national news, business news, technological news and other news coverage.
 

©2021 Cambodian Tribune

Menu

  • Home
  • About Us
  • Contact Us
  • Submit News